The market's opinion of the business has improved over the past five years, reflecting a track record of earnings growth. The company's strategy appears to be drawing new investors, with an average annual return of 10% over five years.
Gainers: •$Checkmate Pharmaceuticals(CMPI.US)$+331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash) •$Axsome Therapeutics(AXSM.US)$+27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder) •$超微電腦(SMCI.US)$+14.3% (earnings report) •$普拉格能源(PLUG.US)$+9.24% (t...